Ann: Company & Phase 3 Expansion Update & App 3Z, page-16

First 16 Last

Share
Profile

Follow
Grug57

395 Posts.

21

04/09/18

21:34

Post #: 35415038
Share

Originally posted by rocket973 ↑

These clowns can't even write/check the details of the announcement. Unless its correct that
"Long lead items ordered from China with fabrication underway – first items due to arrive on site Q4 2019"
I was starting to think that maybe these idiots would get back on track, but when you realise that they're so dumb that
1) don't check announcement details
OR
2) the items don't actually arrive on site Q4 2019

The cost blowout was always going to happen, so its no wonder that First Samuel has spat the dummy. They are in so deep that the mud is now over their heads. It was either stump up the money or go broke.

The statement "improvements will see a significant improvement in designed availability, plant throughput and finished product grades and yields." Just another announcement thats a load of waffle.
1) What will be the plant throughput be ie tonnes/hr or tonnes/day
2) what will be the finished products grades and yield be. 56% 58% 60% ?????

If IOR has spent money for the plant design and capital review, then surely that information should be announced. Not just more BS.

The Financing, what an absolute disaster
" End of term payment amount (at any stage up to 3 years): face value + interest accrued + A$1m payment"

Either IOR will have to repay the amount of $6 million + $2 million ( compound 10% interest) +$1 million = $9 million in 3 years time, basically impossible
OR shares in IOR possibly 120 million shares ( pre consolidated 1.8 billion)
So IOR is basically selling half the company for an extra $6 million loan.
Good luck boys , you'll need it.

Expand

How did you calculate 120m shares?

IOR Price at posting: 8.7¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 74 more messages in this thread...

First 16 Last

Add ELE (ASX) to my watchlist

Ann: Company & Phase 3 Expansion Update & App 3Z, page-16

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News